Analysis of Patient Outcomes following Curative R0 Multiorgan Resections for Locally Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
-
Published:2024-05-20
Issue:10
Volume:13
Page:3010
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Dejeu Viorel1, Dejeu Paula2, Muresan Anita3, Bradea Paula4, Dejeu Danut35
Affiliation:
1. Bariatric Surgery Department, Life Memorial Hospital, Calea Grivitei 365, 010719 Bucuresti, Romania 2. Laboratory Medicine Unit, Betania Medical Center, Menumorut 12, 410004 Oradea, Romania 3. Surgical Oncology Department, Emergency County Hospital Oradea, Strada Gheorghe Doja 65, 410169 Oradea, Romania 4. Gastroenterology Unit, Betania Medical Center, Menumorut 12, 410004 Oradea, Romania 5. Bariatric Surgery Department, Medlife Humanitas Hospital, Strada Frunzisului 75, 400664 Cluj Napoca, Romania
Abstract
Background: This systematic review examines the efficacy of multiorgan resection (MOR) in treating locally advanced gastric cancer (LAGC), focusing on survival outcomes, postoperative morbidity, and mortality. Methods: We conducted a comprehensive search of studies in PubMed, Scopus, and Embase up to November 2023, based on the PRISMA guidelines. The inclusion criteria focused on clinical trials, observational studies, case–control studies, and qualitative research, involving patients of any age and gender diagnosed with LAGC undergoing MOR aimed at R0 resection, with secondary outcomes focusing on survival rates, postoperative outcomes, and the effects of adjuvant and neoadjuvant therapies. Exclusion criteria ruled out non-human studies, research not specifically focused on LAGC patients undergoing MOR, and studies lacking clear, quantifiable outcomes. The quality assessment was performed using the Newcastle–Ottawa Scale. The final analysis included twenty studies, involving a total of 2489 patients across a time span from 2001 to 2023. Results highlighted a significant variation in median survival times ranging from 10 to 27 months and R0 resection rates from 32.1% to 94.3%. Survival rates one-year post-R0 resection varied between 46.7% and 84.8%, with an adjusted weighted mean of 66.95%. Key predictors of reduced survival included esophageal invasion and peritoneal dissemination, the presence of more than six lymph nodes, and tumor sizes over 10 cm. Nevertheless, the meta-analysis revealed a significant heterogeneity (I2 = 87%), indicating substantial variability across studies, that might be caused by differences in surgical techniques, patient demographics, and treatment settings which influence survival outcomes. Results: The review underlines the important role of achieving R0 resection status in improving survival outcomes, despite the high risks associated with MOR. Variability across studies suggests that local practice patterns and patient demographics significantly influence results. Conclusions: The findings emphasize the need for aggressive surgical strategies to improve survival in LAGC treatment, highlighting the importance of achieving curative resection despite inherent challenges.
Reference50 articles.
1. Zurlo, I.V., Basso, M., Strippoli, A., Calegari, M.A., Orlandi, A., Cassano, A., Di Salvatore, M., Garufi, G., Bria, E., and Tortora, G. (2020). Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren’s Classification in Pan-Cancer Analysis Era?. Cancers, 12. 2. Yeh, J.H., Yeh, Y.S., Tsai, H.L., Huang, C.W., Chang, T.K., Su, W.C., and Wang, J.Y. (2022). Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?. Cancers, 14. 3. Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm phase 2 trial;Wei;Nat. Commun.,2023 4. Recent Estimates and Predictions of 5-Year Survival in Patients with Gastric Cancer: A Model-Based Period Analysis;Li;Cancer Control.,2022 5. Mukkamalla, S.K.R., Recio-Boiles, A., and Babiker, H.M. (2023, November 13). Gastric Cancer, Available online: https://www.ncbi.nlm.nih.gov/books/NBK459142/.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|